Tacabrutideg in Modern Hematology: Emerging Considerations for Evidence-Based Clinical Practice
Even though many novel targeted therapies for B-cell malignancies have been introduced to the market, many cases of B-cell malignancies still are resistant to treatment or progress despite therapy with single agents